High Acceptability and Perceived Feasibility of Long-Acting Injectable Antiretroviral Treatment Among People Living with HIV Who Are Viremic and Health Workers in Uganda

• Published in: AIDS patient care and STDs Vol. 37; no. 6; p. 316
• Main Authors: Kennedy, Caitlin E, Zhao, Tongying, Vo, Anh Van, Nakubulwa, Rosette, Nabakka, Proscovia, Jackson, Jade, Rosen, Joseph G, Chang, Larry W, Reynolds, Steven J, Quinn, Thomas C, Nakigozi, Gertrude, Kigozi, Godfrey, Kagaayi, Joseph, Nalugoda, Fred, Ddaaki, William G, Grabowski, M Kate, Nakyanjo, Neema
• Format: Journal Article
• Language: English
• Published: United States 01.06.2023
• Subjects: Anti-HIV Agents - therapeutic use; Anti-Retroviral Agents - therapeutic use; Feasibility Studies; HIV Infections - drug therapy; Humans; Trust; Uganda; Viremia - drug therapy; Uganda; Uganda; long-acting antiretroviral therapy; injectable cabotegravir/rilpivirine; viremia
• DOI: 10.1089/apc.2023.0017

Long-acting injectable antiretroviral treatment (LAI ART), such as a bimonthly injection of cabotegravir/rilpivirine, is a promising HIV treatment option. LAI ART may particularly benefit people who are reluctant to initiate or are poorly adherent to daily oral pills and not virally suppressed. However, the acceptability and feasibility of LAI ART among individuals with viremia in Africa has not been well studied. We conducted qualitative in-depth interviews with 38 people living with HIV with viral load ≥1000 copies/mL and 15 medical and nursing staff, and 6 focus group discussions with peer health workers, to examine acceptability and feasibility of LAI ART in south-central Uganda. Transcripts were thematically analyzed through a team-based framework approach. Most people living with HIV reacted positively toward LAI ART and endorsed interest in taking it themselves. Most felt LAI ART would make adherence easier by reducing the challenge with remembering daily pills, particularly in the context of busy schedules, travel, alcohol use, and dietary requirements. Participants also appreciated the privacy of injections, reducing the likelihood of stigma or inadvertent HIV serostatus disclosure with pill possession. Concerns about LAI ART included side effects, perceived medication effectiveness, fear of injection, and medical mistrust and conspiracy beliefs. Health workers and participants with viremia also noted health system challenges, such as stockouts and monitoring treatment failure. However, they felt the health system could overcome these challenges. Implementation complexities must be addressed as LAI ART is introduced and expanded in Africa to best support viral suppression and address HIV care continuum gaps.